Positive data on the Cambridge company's Alzheimer's drug released late Tuesday restored some investor and analyst confidence. But patient advocates are holding out for full study results.
Positive data on the Cambridge company's Alzheimer's drug released late Tuesday restored some investor and analyst confidence. But patient advocates are holding out for full study results.
